BIOMAT Database Logo BIOMAT Database Logo

Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. 1988

B R Murphy, and G A Prince, and P L Collins, and K Van Wyke Coelingh, and R A Olmsted, and M K Spriggs, and R H Parrott, and H W Kim, and C D Brandt, and R M Chanock
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Vaccines against parainfluenza (PIV) and respiratory syncytial viruses (RSV) that are currently being developed include both live and subunit vaccines. Candidate live PIV vaccines that have been found to be attenuated and efficacious in rodents or primate models are (1) cold-adapted, temperature-sensitive mutants of PIV-type 3 that have been serially passaged at low temperature (20 degrees C) in simian kidney tissue culture; (2) protease-activation mutants (PIV-1-Sendai), which have mutations that decrease the cleavability of their F glycoprotein by host cell protease; (3) an animal virus, bovine PIV-3 virus, which is antigenically related to the human PIV-3 virus, and (4) vaccinia recombinant viruses bearing RSV or PIV-3 glycoproteins. Subunit RSV and PIV-3 viruses are being produced and evaluated as immunogens. A major concern with these vaccines is the possibility of disease potentiation following virus infection as occurred previously with formalin-inactivated measles and RSV vaccines. Studies indicate that PIV-3 and RSV glycoprotein vaccines are immunogenic and efficacious in animals but insufficient data exist to estimate their capacity to potentiate disease. However, since a cotton rat model is available to detect potentiated disease resulting from infection of cotton rats previously immunized with formalin-inactivated RSV vaccine, it is now possible to systematically evaluate new vaccines in experimental animals for disease potentiation before studies are initiated in humans. It is likely within the next several years that one or more of these PIV or RSV vaccines will be tested in humans for safety and immunogenicity.

UI MeSH Term Description Entries
D010253 Respirovirus Infections Infections with viruses of the genus RESPIROVIRUS, family PARAMYXOVIRIDAE. Host cell infection occurs by adsorption, via HEMAGGLUTININ, to the cell surface. Infections, Respirovirus
D012136 Respiratory Syncytial Viruses A group of viruses in the PNEUMOVIRUS genus causing respiratory infections in various mammals. Humans and cattle are most affected but infections in goats and sheep have also been reported. Chimpanzee Coryza Agent,Orthopneumovirus,RSV Respiratory Syncytial Virus,Chimpanzee Coryza Agents,Coryza Agent, Chimpanzee,Orthopneumoviruses,Respiratory Syncytial Virus,Syncytial Virus, Respiratory,Virus, Respiratory Syncytial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral
D014765 Viral Vaccines Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease. Viral Vaccine,Vaccine, Viral,Vaccines, Viral
D018108 Respirovirus A genus of the family PARAMYXOVIRIDAE (subfamily PARAMYXOVIRINAE) where all the virions have both HEMAGGLUTININ and NEURAMINIDASE activities and encode a non-structural C protein. SENDAI VIRUS is the type species. Respiroviruses
D018184 Paramyxoviridae Infections Infections with viruses of the family PARAMYXOVIRIDAE. This includes MORBILLIVIRUS INFECTIONS; RESPIROVIRUS INFECTIONS; PNEUMOVIRUS INFECTIONS; HENIPAVIRUS INFECTIONS; AVULAVIRUS INFECTIONS; and RUBULAVIRUS INFECTIONS. Parainfluenza,Parainfluenza Virus Infections,Infections, Paramyxoviridae,Infection, Parainfluenza Virus,Infection, Paramyxoviridae,Infections, Parainfluenza Virus,Parainfluenza Virus Infection,Paramyxoviridae Infection,Virus Infection, Parainfluenza,Virus Infections, Parainfluenza

Related Publications

B R Murphy, and G A Prince, and P L Collins, and K Van Wyke Coelingh, and R A Olmsted, and M K Spriggs, and R H Parrott, and H W Kim, and C D Brandt, and R M Chanock
Current approaches to the development of vaccines effective against parainfluenza viruses.
January 1988, Bulletin of the World Health Organization,
B R Murphy, and G A Prince, and P L Collins, and K Van Wyke Coelingh, and R A Olmsted, and M K Spriggs, and R H Parrott, and H W Kim, and C D Brandt, and R M Chanock
Respiratory virus vaccines. I. Respiratory syncytial and parainfluenza virus vaccines.
April 1966, The American review of respiratory disease,
B R Murphy, and G A Prince, and P L Collins, and K Van Wyke Coelingh, and R A Olmsted, and M K Spriggs, and R H Parrott, and H W Kim, and C D Brandt, and R M Chanock
Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development.
March 1995, Vaccine,
B R Murphy, and G A Prince, and P L Collins, and K Van Wyke Coelingh, and R A Olmsted, and M K Spriggs, and R H Parrott, and H W Kim, and C D Brandt, and R M Chanock
Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.
December 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
B R Murphy, and G A Prince, and P L Collins, and K Van Wyke Coelingh, and R A Olmsted, and M K Spriggs, and R H Parrott, and H W Kim, and C D Brandt, and R M Chanock
An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines.
April 1994, Virus research,
B R Murphy, and G A Prince, and P L Collins, and K Van Wyke Coelingh, and R A Olmsted, and M K Spriggs, and R H Parrott, and H W Kim, and C D Brandt, and R M Chanock
RESPIRATORY DISEASE ASSOCIATED WITH PARAINFLUENZA AND RESPIRATORY SYNCYTIAL VIRUSES.
August 1964, The New Zealand medical journal,
B R Murphy, and G A Prince, and P L Collins, and K Van Wyke Coelingh, and R A Olmsted, and M K Spriggs, and R H Parrott, and H W Kim, and C D Brandt, and R M Chanock
Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.
July 2002, The Journal of clinical investigation,
B R Murphy, and G A Prince, and P L Collins, and K Van Wyke Coelingh, and R A Olmsted, and M K Spriggs, and R H Parrott, and H W Kim, and C D Brandt, and R M Chanock
Serological responses in calves to vaccines against bovine respiratory syncytial, infectious bovine rhinotracheitis, bovine viral diarrhoea and parainfluenza-3 viruses.
January 1996, Developments in biological standardization,
B R Murphy, and G A Prince, and P L Collins, and K Van Wyke Coelingh, and R A Olmsted, and M K Spriggs, and R H Parrott, and H W Kim, and C D Brandt, and R M Chanock
Pulmonary infections with respiratory syncytial virus and the parainfluenza viruses.
June 1987, Seminars in respiratory infections,
B R Murphy, and G A Prince, and P L Collins, and K Van Wyke Coelingh, and R A Olmsted, and M K Spriggs, and R H Parrott, and H W Kim, and C D Brandt, and R M Chanock
Development of effective subunit vaccines against enveloped viruses.
January 1980, Progress in clinical and biological research,
Copied contents to your clipboard!